- Finland has suspended the use of the Moderna COVID-19 vaccine for younger men after some suffered from heart inflammations
- Finland will instead vaccinate younger men with the Pfizer brand, said Mika Salminen, the Finnish health institute’s director
- The U.S. Centers for Disease Control and Prevention earlier said that the benefits of being vaccinated against COVID-19 outweigh the risks, such as presented in the study of the Moderna vaccine
HELSINKI: Finland has suspended the use of the Moderna COVID-19 vaccine for younger men after some suffered from heart inflammations.
A study is to be published within weeks that indicates that men under 30 years old displayed a “slightly higher risk than others of developing myocarditis” after receiving the Moderna vaccine.
Finland will instead vaccinate younger men with the Pfizer brand, said Mika Salminen, the Finnish health institute’s director.
In commenting on the study, Moderna released a statement, saying the incidents “are typically mild cases and individuals tend to recover within a short time following standard treatment and rest.”
“The risk of myocarditis is substantially increased for those who contract COVID-19, and vaccination is the best way to protect against this,” the company added.
Meanwhile, Sweden announced on Wednesday that they would temporarily stop the use of the Moderna vaccine for all young adults and children, based upon the Finnish study.
Myocarditis is an inflammation of the heart muscle, with symptoms including chest pain, shortness of breath and feelings of having an abnormal heartbeat.
The U.S. Centers for Disease Control and Prevention earlier said that the benefits of being vaccinated against COVID-19 outweigh the risks, such as presented in the study of the Moderna vaccine.
